REPORT ON THE RESULTS OF THE FOUNDATION'S ACTIVITIES

2020

CANCER foundation

rakfond.org

Advancing the Day when Cancer is Defeated



CONTENTS

1. EXECUTIVE SUMMARY

Foundation's Activities in 2020



The global pandemic has significantly influenced our work in 2020. We had to cancel some of our fundraising initiatives and postpone the competition of research projects in radiation therapy.

Thanks to your support and tremendous joint effort, regardless of the difficulties that the whole world continues to face, we managed to retain our team, attract new partners, and continue to support scientific research in oncology. RakFond's grants to individuals are now exempt from taxation.

GRANTS

Competition in radiotherapy	04 February – 31 May 2020
RFP	2020-01
Postponed and combined with RFP 2020-02	
Competition of research projects	01 July – 11 November 2020
RFP	2020-02

Winner (see slide 12 for details):

- Yana Mangasarova: 822 000 RUR (project summary)

TEAM

Boards: - Directors: 3; - Trustees: 5; - Scientific Advisors: 17
Volunteers: a team of permanent and temporary via ProCharity
Meet our team on rakfond.org

FINANCIALS[1]

Total funds raised:	**1 479 896 RUR**
• Corporate	606 825 RUR
• Individuals	312 570 RUR
• Non-profit «Nuzhna Pomosch»	380 055 RUR
• Meet for Charity Auctions	161 000 RUR
• Other (return of funds)	19 446 RUR
Expenses:	**1 198 107 RUR**
• **Grants:**	411 000 RUR
additionally reserved	411 000 RUR
• **Salary:**	649 414 RUR
• **Other administrative:**	137 693 RUR

CORONAVIRUS IMAGE CREDIT: ALISSA ECKERT, DAN HIGGINS/CDC

[1]data from non-audited financial statements of the Foundation for Cancer Research Support in 2020

Foundation's Grantees

Emil Bulatov, Ph.D.
Leading Researcher at Kazan Federal University

"RakFond's work is critical to support new breakthrough research that will lead to more effective and affordable drugs treating hundreds and thousands of patients."

"Work of organizations such as RakFond gives young professionals an opportunity to try and implement projects that allow them to advance the study of diagnostics and treatment of cancer."

Mariya Stepanova, M.D.
Oncologist, Head of Department of the Out-Patient Division at Clinic LUCH LLC,
Junior Research Fellow at St. Petersburg Clinical Research and Practical Center for Specialized Types of Medical Care (Oncologic)

Foundation's Grantees



Yana Mangasarova, M.D., Ph.D.
Hematologist, Head of Out-Patient Clinic for Intensive High-Dose Chemotherapy of Hematologic Malignancies at National Medical Research Center of Hematology

"It is great that there is RakFond with its transparent competition of projects, with its scrupulous expert assessment of our work and professional advice from experts – we receive not only project funding, but also the support of specialists working in the field of oncology"

"RakFond's grant is an opportunity to achieve results through teamwork with people from RakFond whose ideas match my own. Only joint efforts can give results that cannot be achieved individually."

Natalia Risinskaya, Ph.D.
Senior Research Fellow of the Molecular Hematology Lab at National Medical Research Center of Hematology

2. OPERATIONS REPORT

FUNDING CANCER RESEARCH

Completed and ongoing studies in 2020 (grants of 2019):

Emil Bulatov, Kazan Federal University

Project: Investigating efficacy mechanisms of T cells with chimeric antigen receptor (CAR-T) against solid tumors – summary

Funding: 100 000 RUR + reagents from SciStoreLab

Natalya Risinskaya, National Medical Research Center of Hematology

Project : Loss of heterozygosity in the short tandem repeat (STR) loci found in tumor DNA of ALL patients as a factor predicting poor outcome – summary

Funding: 250 000 RUR

Alexey Rumyantsev, N. N. Blokhin National Medical Research Center of Oncology

Project: Randomized multicenter phase II trial to assess the efficacy of platinum-based chemotherapy vs standard non-platinum therapy in patients with platinum-resistant recurrent ovarian cancer (EPITROC) – summary

Amount of funding : 463 000 RUR

RESULTS OF THE SUPPORTED RESEARCH

INVESTIGATING EFFICACY MECHANISMS OF T CELLS WITH CHIMERIC ANTIGEN RECEPTOR (CAR-T) AGAINST SOLID TUMORS



The project, funded by the Foundation for Cancer Research Support, is a part of a large study supported by the Russian Science Foundation and conducted jointly with the V.A. Almazov National Research Center (St. Petersburg). The main objective of the study is to elucidate the mechanisms of action of CAR-T cells in cellular and animal models of solid tumors.

Preliminary experiments on xenograft animal models with the orthotopic tumor have been completed, and the results are very encouraging. The data obtained in cell models of solid tumors were generally confirmed in subsequent experiments with immunodeficient mice. The CAR-T cells were non-toxic for mice and resulted in a marked reduction of the tumor size.

The ongoing work will bring us closer to the development of domestic CAR-T cell products that will treat cancer patients and save their lives.

The development of CAR-T cell products against solid tumors is carried out at the Drug Discovery Center, and the first steps of translating the results into clinical practice will take place at the Clinical Research Center for Precision and Regenerative Medicine of Kazan Federal University.

More on research results: https://bit.ly/2S8JfYg

INTERIM RESULTS OF SUPPORTED RESEARCH

LOSS OF HETEROZYGOSITY IN THE SHORT TANDEM REPEAT (STR) LOCI FOUND IN TUMOR DNA OF ALL PATIENTS AS A FACTOR PREDICTING POOR OUTCOME

Loss of heterozygosity (LOH) in patients' tumor DNA is not included in the standard list of tests, and it's mostly detected accidentally.

A specific study on a large setting of de novo diagnosed patients with a common diagnosis and treatment was conducted in order to prove that the LOH in STR loci reflects serious hidden chromosomal events and has an impact on the outcome of the disease.

Evaluation of overall and event-free survival demonstrated that LOH is an independent factor of poor prognosis. STR profiling is an affordable and simple method for the integral assessment of changes in the tumor genome. Based on the results of the study, this method may gradually be adopted into the routine practice of molecular studies in acute leukemia in addition to standard cytogenetics or even as a main method for assessing DNA from archival materials when a cytogenetic analysis is simply impossible to perform.

In addition to the undoubted practical significance of the obtained results, this study has also helped to expand the understanding of the nature of cell malignancy.

The continuation of the study will allow to expand the study cohort of patients for identification of STR markers, where LOH has the greatest impact on the outcome of the disease.

More on interim research results: https://bit.ly/2S9mhQP

COMPETITIONS AND GRANTS

FIRST COMPETITION **RFP: 2020-01** **Postponed** • Pre-registration required • Application limited to 7 pages	**COMPETITION OF RESEARCH PROJECTS IN RADIATION THERAPY IN ONCOLOGY** Priority research areas (do not limit other proposals to be submitted for the competition): • Radiation therapy (RT) in combination with drug therapy, including immunotherapy; • Predictive biomarkers of radiation sensitivity and high risk of radiation complications; • Supportive care in patients receiving RT.
Budget	1 000 000 RUR divided into two payments of up to 500 000 RUR annually
Timeline	**Applications open date:** 4 February 2020 **Applications due date:** 31 May 2020 **Notice of award:** 31 August 2020

SECOND COMPETITION **RFP: 2020-02** **Completed** • Pre-registration required • Application limited to 7 pages	**COMPETITION OF RESEARCH PROJECTS IN ONCOLOGY** 1. Clinical trials: interventional, randomized (preferred), in cancer prevention, diagnostics, monitoring, and treatment, rehabilitation and quality of life. 2. Translational studies: diagnostic and prognostic biomarkers, treatment selection. 3. RT in oncology: RT in combination with drug therapy, including immunotherapy; predictive biomarkers of radiation sensitivity and high risk of radiation complications; supportive care in patients receiving RT.
Budget	1 000 000 RUR divided into two payments of up to 500 000 RUR annually
Timeline	**Applications open date:** 1 July 2020 **Applications due date:** 20 September 2020 **Notice of award:** 11 November 2020

AWARD WINNER
RFP 2020-02

YANA MANGASAROVA

National Medical Research Center of Hematology

Project: Search for the markers of microsatellite instability that are diagnostically significant in aggressive lymphomas

Funding: 822 000 RUR

Description:
https://www.rakfond.org/en/mangasarova_2020_02_en/

EXPERT SUPPORT OF RESEARCH

CHRONOS19: Non-interventional cohort study "Registry of patients with hematologic disease and COVID-19 in Russia"

Национальный медицинский исследовательский центр гематологии

CANCER foundation
rakfond.org
Advancing the Day when Cancer is Defeated

On the online platform ENROLLME

Main objective:

To determine treatment outcomes in patients with hematologic disease and COVID-19, which would help to develop approaches to management of these patients.

Enrolled: 575 patients

Interim results were presented at the American Society of Hematology (ASH) Annual Meeting, where the study was recognized with a special award.

Data collection is ongoing, full-text publications and presentation of updated results are being prepared

Participating centers:

National Research Center for Hematology (Moscow)
S.P. Botkin City Clinical Hospital (Moscow)
City Clinical Hospital n. a. V.V. Veresaev (Moscow)
N.V. Sklifosovsky Emergency Medicine Institute (Moscow)
Regional Clinical Hospital #2 (Vladivostok)
Republican Clinical Hospital #4 (Saransk)
Regional Clinical Hospital (Yaroslavl)
RM Gorbacheva Research Institute, Pavlov University (St. Petersburg)
N.A. Semashko Republican Clinical Hospital (Ulan-Ude)
Regional Clinical Hospital (Ekaterinburg)
Republican Clinical Hospital of Tatarstan (Kazan)
Regional Clinical Hospital (Vladimir)
N.A. Semashko Regional Clinical Hospital (Nizhniy Novgorod)
Regional Hospital (Novosibirsk)
Regional Clinical Hospital (Omsk)
Republican Hospital #1 (Yakutsk)

EXPERT SUPPORT OF RESEARCH

Original Article | Published: 20 February 2020

Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection

Ilya Tsimafeyeu, Rustem Gafanov, Svetlana Protsenko, Anna Semenova, Ani Oganesyan, Nurzhan Nurgaliyev, Sergei Krasny, Anastasia Bondarenko, Sufia Safina & Kristina Zakurdaeva

Cancer Immunology, Immunotherapy **69**, 983–988(2020) | Cite this article

This observational study of efficacy and safety of immunotherapy in patients with kidney cancer and chronic hepatitis C virus (HCV) infection demonstrated superior efficacy of treatment with an immune checkpoint inhibitor (nivolumab) which was well tolerated. The efficacy and safety profiles observed in this study support the administration of nivolumab in patients with metastatic renal cell carcinoma infected with HCV and warrant further investigation.

Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma

A Phase 2 Randomized Study FARETES

Tsimafeyeu, Ilya MD[*,†]; Tishova, Yulia MD, PhD[‡]; Zukov, Ruslan MD, PhD[§]; Borisov, Pavel MD, PhD[ǁ]; Bondarenko, Anastasia MD[¶]; Zakurdaeva, Kristina MD, PhD[#] **Author Information**

American Journal of Clinical Oncology: January 27, 2021 - Volume Publish Ahead of Print - Issue -

A Phase 2 multicenter, randomized clinical trial of testosterone for managing fatigue in male patients with kidney cancer and hypogonadism who receive targeted therapy. An improved quality of life and better symptom control were observed in patients receiving testosterone, which is certainly important for maintaining the general well-being of patients during anticancer treatment.

EVENTS AND MATERIALS

XXIV RUSSIAN ONCOLOGY CONGRESS



RUSSCO and RakFond Session on Practice-Changing Academic Research in Oncology

BROCHURE

for researchers on the regulatory support of clinical trials (prepared jointly with ACTO and RUSSCO)



View pdf

OBSTACLES IN RUSSIAN MEDICAL SCIENCE

read the material in Vedomosti

ARTICLES & REVIEWS

about recent scientific advances in oncology

Read and watch

SERIES OF INTERVIEWS WITH EXPERTS

Watch interviews

3. FUNDRAISING & FINANCIALS

FINANCIAL REPORT 2020

Total funds raised in 2020: 1 479 896 RUR[1]

FUNDING BY SOURCE



MFC=Meet For Charity

*including partial return of grant (Grant Agreement 05/2019) - 1 971 RUR, return of overpaid taxes, rent deposit

FULL REPORT 2020

Expenditures: 1 198 107 RUR[1]

1. Research funding — 411 000 RUR

✓ Research Grant 2020-02 — 411 000 RUR

RESERVED an additional 411,000 RUR for the second part of the grant funding under program (RFP) 2020-02

By the Decree of the Russian Government as of March 21, 2020, Foundation's grants to individuals were exempted from taxation.

2. Administrative expenses — 787 107 RUR

- payroll – 649 414 RUR
- rent – 38 226 RUR
- accounting and legal support – 66 900 RUR
- bank charges – 10 107 RUR
- audit – 22 460 RUR

[1]data from non-audited financial statements of the Foundation for Cancer Research Support in 2020

4. PARTNERSHIPS & COLLABORATIONS

Our Partners

ПРОВЕРЕНО ФОНДОМ «НУЖНА ПОМОЩЬ»

НУЖНА ПОМОЩЬ

Fundraising
nuzhnapomosh.ru/

ЭНРОЛЛМИ
КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ

Online platform for clinical trials management
enrollme.ru

UNIM
СТАНДАРТ ОНКОЛОГИЧЕСКОЙ ДИАГНОСТИКИ

unim.su

РОССИЙСКОЕ ОБЩЕСТВО КЛИНИЧЕСКОЙ ОНКОЛОГИИ
RUSSCO

Strategic Cooperation
rosoncoweb.ru

PRO CHARITY

Professional match of volunteers
procharity.ru

SCI STORE

Joint competition
sci-store.ru

OCT

oct-clinicaltrials.com

Data MATRIX

dm-matrix.com

Сеченовский Университет

ADMINVPS
все включено!

adminvps.ru

Экзактэ Лабс

exactelabs.com

UART
ТЫ И ИСКУССТВО

Information Support
u-art.ru

MFC
MEET FOR CHARITY

Fundraising
meetforcharity.today

GOSH CREATIVE LABORATORY projects

goshprojects.org

NOMIA

nomia.net

CONTACTS

E-mail: info@rakfond.org

Foundation's Director:
Yuliya Atamanyuk | director@rakfond.org

Founder and Chair of the Board of Directors:
Kristina Zakurdaeva | christina@rakfond.org

Funding & Partnerships:
| finance@rakfond.org

Funding programs
| grant@rakfond.org

Volunteering:
Maria Shevchenko | volunteer@rakfond.org

Mass media and public relationships:
| media@rakfond.org

CANCER foundation

rakfond.org/en

Advancing the Day when Cancer is Defeated

rak_fond

RakFond

www.rakfond.org